Allarity Therapeutics, Inc. ALLR
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Allarity Therapeutics, Inc. (ALLR) is a healthcare company listed in the US with a market value of about $15M. In the twelve months to September 30, 2026 it had revenue of $350000 and net income of -$16M, a net margin of -4493.7%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -416%.
About Allarity Therapeutics
Allarity Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations. It was profitable in 0 of the last 6 years in our data. Its share count rose by 211200% over three years (dilution for shareholders). It spends 2063% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $350000 | $320000 | $0 | — | — | — | — |
| Net income | -$16M | -$11M | -$25M | -$12M | -$16M | -$27M | -$7M |
| Free cash flow | -$13M | -$15M | -$18M | -$13M | -$17M | — | -$7M |
| EPS (diluted) | $-0.98 | $-0.78 | $-15.65 | $-10.26 | $-3093.42 | $-5866.07 | $-2842.03 |
| Net margin | -4493.7% | -3509.7% | — | — | — | — | — |
| ROIC | — | -112.3% | -203.8% | — | -1239.9% | -108.9% | -23.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 1 analysts is $11.00, 1053% above the current price; targets range from $11.00 to $11.00; the consensus rating is “none”; expected EPS is $-0.80 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Allarity Therapeutics pay a dividend?
Not currently.
Is Allarity Therapeutics a good stock to buy?
We do not give buy or sell advice. Allarity Therapeutics scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.